Related News
FDA approves first canine cancer drug
Source: Agencies |
June 4, 2009, Thursday
|
Print Edition
Print Edition
THE United States Food and Drug Administration has approved the first drug made specifically to treat cancer in dogs.
Until now, all cancer drugs used in veterinary medicine were developed for use in humans and were not specifically approved for animals. Federal law allows veterinarians to administer cancer medicines and other human treatments under controlled circumstances.
The new drug, Palladia, manufactured by Pfizer Animal Health Inc, has been approved to treat a type of cancer that accounts for about one in five cases of canine skin tumors.
Canine cutaneous mast cell tumors can appear small and insignificant when dogs have them.
Some are easily removed, but others can lead to life-threatening disease, according to the FDA.
"This cancer drug approval for dogs is an important step forward for veterinary medicine," Bernadette Dunham, director of FDA's center for veterinary medicine, said yesterday.
"Prior to this approval, veterinarians had to rely on human oncology drugs, without knowledge of how safe or effective they would be for dogs," Dunham said.
"Today's approval offers dog owners, in consultation with their veterinarian, an option for treatment of their dog's cancer."
Palladia is a tyrosine kinase inhibitor that works by killing tumor cells and cutting off blood supply to the tumor. Common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss and blood in the stool.
Until now, all cancer drugs used in veterinary medicine were developed for use in humans and were not specifically approved for animals. Federal law allows veterinarians to administer cancer medicines and other human treatments under controlled circumstances.
The new drug, Palladia, manufactured by Pfizer Animal Health Inc, has been approved to treat a type of cancer that accounts for about one in five cases of canine skin tumors.
Canine cutaneous mast cell tumors can appear small and insignificant when dogs have them.
Some are easily removed, but others can lead to life-threatening disease, according to the FDA.
"This cancer drug approval for dogs is an important step forward for veterinary medicine," Bernadette Dunham, director of FDA's center for veterinary medicine, said yesterday.
"Prior to this approval, veterinarians had to rely on human oncology drugs, without knowledge of how safe or effective they would be for dogs," Dunham said.
"Today's approval offers dog owners, in consultation with their veterinarian, an option for treatment of their dog's cancer."
Palladia is a tyrosine kinase inhibitor that works by killing tumor cells and cutting off blood supply to the tumor. Common side effects include diarrhea, decrease or loss of appetite, lameness, weight loss and blood in the stool.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
